Companies to Pursue Weapons of Mass Destruction - Defeat Technology, Arms Control, and Nuclear Technology Electromagnetic Research and Development/Survivability and Infrastructure Programs

DELRAY BEACH, Fla., Nov. 6, 2012 (GLOBE NEWSWIRE) -- PositiveID Corporation (" PositiveID") (OTCBB:PSID), an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for diabetes management and rapid medical testing, today announced it has signed a Teaming Agreement ("Teaming Agreement") with Science Applications International Corporation ("SAIC") (NYSE:SAI) to pursue the Defense Threat Reduction Agency ("DTRA") Indefinite Delivery/Indefinite Quantity ("IDIQ") Multiple Award Contracts supporting the Weapons of Mass Destruction ("WMD") - Defeat Technology, Arms Control, and Nuclear Technology Electromagnetic Research and Development/ Survivability and Infrastructure programs.

The Teaming Agreement pairs SAIC's system engineering and integration capabilities with PositiveID's bio-threat detection technologies. PositiveID will offer both its Dragonfly™ Rapid MD-x Cartridge-based diagnostic system (" Dragonfly") as well as its M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector as part of the Teaming Agreement.

PositiveID's Dragonfly system is designed to deliver molecular diagnostic results from a sample in less than 30 minutes, which would enable accurate diagnostics leading to potential treatment scenarios at the point of care that are not possible with existing systems. Dragonfly is being developed further for a broad range of biological detection situations including radiation-induced cell damage within the human body, strains of influenza and other common pathogens and diseases such as E. coli, methicillin-resistant staphylococcus aureus ("MRSA") and human papilloma virus ("HPV").

PositiveID's M-BAND, developed under contract for the Department of Homeland Security Science and Technology Division, is a bioaerosol monitor with fully integrated systems with sample collection, processing and detection modules that continuously analyze air samples for the detection of bacteria, viruses, and toxins with results in as little as two hours. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments in the aggregate.

William J. Caragol, Chairman and CEO of PositiveID, stated, "We are very pleased to team with SAIC through this agreement, and demonstrate the value and capabilities of our Dragonfly and M-BAND technologies."

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of airborne bio-threat detection systems for America's homeland defense industry as well as advanced technologies for diabetes management and rapid medical testing. Its wholly-owned subsidiary, Microfluidic Systems, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID's future expectations, including the likelihood that the companies will pursue the DTRA IDIQ Multiple Award Contracts supporting the WMD - Defeat Technology, Arms Control, and Nuclear Technology Electromagnetic Research and Development/ Survivability and Infrastructure programs; the likelihood that PositiveID will offer both its Dragonfly as well as its M-BAND airborne bio-threat detector as part of the Teaming Agreement; the likelihood that PositiveID's Dragonfly is designed to deliver molecular diagnostic results from a sample in less than 30 minutes, which would enable accurate diagnostics leading to potential treatment scenarios at the point of care that are not possible with existing systems; the likelihood that Dragonfly is being developed further for a broad range of biological detection situations including radiation-induced cell damage within the human body, strains of influenza and other common pathogens and diseases such as E. coli, MRSA and HPV; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include PositiveID's ability to successfully pursue the DTRA IDIQ Multiple Award Contracts supporting the WMD - Defeat Technology, Arms Control, and Nuclear Technology Electromagnetic Research and Development/ Survivability and Infrastructure programs; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 28, 2012, as amended on May 4, 2012, and 10-Qs filed on August 20, 2012, as amended on September 12, 2012, May 14, 2012, and November 14, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law. 


CONTACT: PositiveID Corporation

         Allison Tomek

         561-805-8000

         atomek@positiveidcorp.com
Source: PositiveID Corporation

News Provided by Acquire Media

distributed by